Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease. RESULTS: Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49). CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [45]
In the citing paper
“bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47]”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“Clinical trials often fail to deliver benefits.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [57]
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Assessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Research works printed but not linked: 2
- Wimo A, Wetterholm AL, Mastey V, Winbald B. Evaluations of resource utilization and caregiver time in anti-dementia drug trials- a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winbald B, eds. The health economics of dementia. London: John Wiley, 1998:465-99.
- Kind P. 1996. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 101–200 of 1,006
Goyal, D., Shuaib, S., Mann, S., & Goyal, B. (2017) · ACS Combinatorial Science · doi:10.1021/acscombsci.6b00116 · Cited by 227
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
Xiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00795-7 · Cited by 224
“Although repeated failures of phase 3 clinical trials in the last decade have been reported[7, 8], much effort continues to be invested in developing treatments for this disease[9].”
BackgroundA review on advances of treatment modalities for Alzheimer's disease
Se Thoe, E., Fauzi, A., Tang, Y. Q., Chamyuang, S., & Chia, A. Y. Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119129 · Cited by 219
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170560 · Cited by 219
“as monotherapy or as add-on therapy was also compared with that reported for mild AD in the placebo arms of recent Phase III studies [21, 22] and currently available ADNI data (https://ida.”
ResultMacdonald, R., Barnes, K., Hastings, C., & Mortiboys, H. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170501 · Cited by 217
Park, J.-C., Jang, S.-Y., Lee, D., Lee, J., Kang, U., Chang, H., Kim, H. J., Han, S.-H., Seo, J., Choi, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20440-5 · Cited by 211
Park, J.-H., Ju, Y. H., Choi, J. W., Song, H. J., Jang, B. K., Woo, J., Chun, H., Kim, H. J., Shin, S. J., Yarishkin, O., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav0316 · Cited by 216
Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
Recent progress of drug nanoformulations targeting to brain
Khan, A. R., Yang, X., Fu, M., & Zhai, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.004 · Cited by 213
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
“We also recall that solanezumab, developed to remove soluble forms of Aβ, did not meet primary endpoints in two phase III studies [66].”
BackgroundGenetics of Alzheimer’s Disease
Chouraki, V., & Seshadri, S. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00005-6 · Cited by 209
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197
“The first two strategies were generally successful at reducing ARIA incidence; however, despite the ability to use much higher doses of the newer IgG4 antibodies, such as cren-ezumab 25 and solanezumab, 26 these trials produced little evidence of amyloid reduction or clinical efficacy.”
Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment
Hane, F. T., Robinson, M., Lee, B. Y., Bai, O., Leonenko, Z., & Albert, M. S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160907 · Cited by 197
“evaluated in two phase III, double blind, randomized, placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) in mild to moderate AD patients [125].”
MethodRevised criteria for the diagnosis and staging of Alzheimer’s disease
Jack, C. R., Andrews, S. J., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02988-7 · Cited by 193
Self-citationTreatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery
Pardridge, W. M. (2020) · Pharmaceuticals · doi:10.3390/ph13110394 · Cited by 194
“Solanezumab, which failed in AD clinical trials, is a AAA that was said to have a high level of target engagement in AD [100].”
BackgroundFunctional enhancer elements drive subclass-selective expression from mouse to primate neocortex
Mich, J. K., Graybuck, L. T., Hess, E. E., Mahoney, J. T., Kojima, Y., Ding, Y., Somasundaram, S., Miller, J. A., Kalmbach, B. E., Radaelli, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108754 · Cited by 193
György, B., Lööv, C., Zaborowski, M. P., Takeda, S., Kleinstiver, B. P., Commins, C., Kastanenka, K., Mu, D., Volak, A., Giedraitis, V., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.03.007 · Cited by 190
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
“A number of recent publications have reviewed Aβ immunotherapies currently in clinical trials, with an emphasis on the efficacy of the drugs for treating AD [178-187], and the clinical results will not be presented in this review, with the exception of an analysis of the brain levels of solanezumab and bapineuzumab in…”
BackgroundBourdenx, M., Koulakiotis, N. S., Sanoudou, D., Bezard, E., Dehay, B., & Tsarbopoulos, A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.003 · Cited by 185
“raising concerns that either treatment was too late in the course of the disease or Ab alone is the wrong target for an effective treatment of AD (Doody et al., 2014; Salloway et al., 2014).”
BackgroundAmyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi, M., Cecchetti, G., Spinelli, E. G., Vezzulli, P., Falini, A., & Agosta, F. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5205 · Cited by 189
Raskin, J., Cummings, J., Hardy, J., Schuh, K., & Dean, R. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150701103107 · Cited by 188
Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy
Javed, I., Peng, G., Xing, Y., Yu, T., Zhao, M., Kakinen, A., Faridi, A., Parish, C. L., Ding, F., Davis, T. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11762-0 · Cited by 187
Fandos, N., Pérez‐Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., Doecke, J., Fowler, C., Masters, C. L., Sarasa, M., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.07.004 · Cited by 187
New Approaches for the Treatment of Alzheimer’s Disease
Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189
“Therefore, the primary analysis population for EXPEDITION 2 was altered to patients with mild AD, but even with this change in primary outcome, the EXPEDITION 2 trial did not show any improvement in score.(33) A third phase III clinical trial, EXPEDITION 3, was designed to further test the observation that solanezumab…”
Tau passive immunization inhibits not only tau but also Aβ pathology
Dai, C.-L., Tung, Y. C., Liu, F., Gong, C.-X., & Iqbal, K. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0227-5 · Cited by 187
Toward personalized cognitive diagnostics of at-genetic-risk Alzheimer’s disease
Coughlan, G., Coutrot, A., Khondoker, M., Minihane, A.-M., Spiers, H., & Hornberger, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901600116 · Cited by 180
Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178
“Across both studies, the incidences of amyloid-related imaging abnormalities (ARIA) with edema (ARIA-E) and with hemorrhage (ARIA-H) were not substantially different between solanezumab and placebo recipients.(57) A third 76-week, phase III study (EXPEDITION-3) was conducted in 2,129 patients with mild AD and biomarke…”
BackgroundReactive astrocytes in Alzheimer’s disease: A double-edged sword
Chun, H., & Lee, C. J. (2018) · Neuroscience Research · doi:10.1016/j.neures.2017.11.012 · Cited by 176
Supersaturation is a major driving force for protein aggregation in neurodegenerative diseases
Ciryam, P., Kundra, R., Morimoto, R. I., Dobson, C. M., & Vendruscolo, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.004 · Cited by 174
The GABAergic system as a therapeutic target for Alzheimer's disease
Calvo‐Flores Guzmán, B., Vinnakota, C., Govindpani, K., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14345 · Cited by 171
Barakos, J., Purcell, D., Suhy, J., Chalkias, S., Burkett, P., Grassi, C. M., Castrillo-Viguera, C., Rubino, I., & Vijverberg, E. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.21 · Cited by 165
“For example, treatment with solanezumab, which binds to soluble monomeric Aβ, was associated with a lower incidence of ARIA than were other anti-Aβ mAbs that target aggregated forms of Aβ (13).”
BackgroundResultInfluentialPhase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease
(2014) · New England Journal of Medicine · doi:10.1056/nejmc1402193 · Cited by 169
Self-citationDetection and treatment of Alzheimer’s disease in its preclinical stage
Rafii, M. S., & Aisen, P. S. (2023) · Nature Aging · doi:10.1038/s43587-023-00410-4 · Cited by 160
Self-citationBouhrara, M., Reiter, D. A., Bergeron, C. M., Zukley, L. M., Ferrucci, L., Resnick, S. M., & Spencer, R. G. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.007 · Cited by 164
Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease
Iaccarino, L., Tammewar, G., Ayakta, N., Baker, S. L., Bejanin, A., Boxer, A. L., Gorno-Tempini, M. L., Janabi, M., Kramer, J. H., Lazaris, A., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.09.016 · Cited by 165
Sex Differences in Alzheimer’s Disease: Insights From the Multiomics Landscape
Guo, L., Zhong, M. B., Zhang, L., Zhang, B., & Cai, D. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.968 · Cited by 164
“Surprisingly, sex-specific analyses were only performed occasionally during AD clinical trial 72 phases, and the importance of considering sex as a critical modulator of patient responses to 73 treatments was vastly under-appreciated (3-6).”
Targeting Fyn Kinase in Alzheimer’s Disease
Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162
Spatial patterns of progressive brain volume loss after moderate-severe traumatic brain injury
Cole, J. H., Jolly, A., de Simoni, S., Bourke, N., Patel, M. C., Scott, G., & Sharp, D. J. (2018) · Brain · doi:10.1093/brain/awx354 · Cited by 160
“For example, structural MRI atrophy measures have been commonly used as outcome measures in clinical trials of neurodegenerative disease treatments (Doody et al., 2014; Salloway et al., 2014).”
MethodCerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S. K., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159
Benzofuran and Indole: Promising Scaffolds for Drug Development in Alzheimer's Disease
Goyal, D., Kaur, A., & Goyal, B. (2018) · ChemMedChem · doi:10.1002/cmdc.201800156 · Cited by 168
Zhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E. (2020) · PLOS ONE · doi:10.1371/journal.pone.0229819 · Cited by 157
“Even with carefully selected patients enrolled in large, multi-center, Phase 3 clinical trials, AD is misdiagnosed based solely on clinical criteria in up to 25% of patients [35, 36].”
BackgroundA phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, N. R., Thomas, R. G., Rissman, R. A., Brewer, J. B., Rafii, M. S., van Dyck, C. H., Jack, C. R., Sano, M., Knopman, D. S., Raman, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003904 · Cited by 157
Self-citationHan, Y., Chu, X., Cui, L., Fu, S., Gao, C., Li, Y., & Sun, B. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1745328 · Cited by 156
“Unfortunately, almost all the Ab-targeting drug candidates have failed in clinical trials (Doody et al., 2013, 2014; Salloway et al., 2014).”
BackgroundPassive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 155
“and memory between the solanezumab-treated and the placebo group (Doody et al. (2014), see Table 1).”
Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update
Yadollahikhales, G., & Rojas, J. C. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01405-0 · Cited by 154
“In phase 3 studies of mild and moderate AD (EXPEDITION and EXPEDITION 2), solanezumab was well-tolerated, with essentially no incidence of amyloid-related imaging abnormalities (ARIA) attributable to the drug, although the agent did not affect the decline in cognition or function compared to placebo [57].”
BackgroundNew roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease
Fuller, J. P., Stavenhagen, J. B., & Teeling, J. L. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00235 · Cited by 154
Mini Mental State Examination and Logical Memory scores for entry into Alzheimer’s disease trials
Chapman, K. R., Bing-Canar, H., Alosco, M. L., Steinberg, E. G., Martin, B., Chaisson, C., Kowall, N., Tripodis, Y., & Stern, R. A. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0176-z · Cited by 152
Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001877 · Cited by 151
“The frequency of amyloidnegative scans in noncarriers (36%) in our study is similar to rates observed in phase 2 trials of florbetaben(14) and florbetapir(15) and phase 3 studies of solanezumab.(16) The GCA in amyloid-negative participants did not change significantly over the course of the study.”
ResultSelf-citationAlzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 150
The Role of Biomarkers in Alzheimer’s Disease Drug Development
Cummings, J. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_2 · Cited by 148
Kim, B., Kim, S., Nam, Y., Park, Y., Shin, S. M., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00465-w · Cited by 187
Cogswell, P. M., Barakos, J. A., Barkhof, F., Benzinger, T. S., Jack, C. R., Poussaint, T. Y., Raji, C. A., Ramanan, V. K., & Whitlow, C. T. (2022) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7586 · Cited by 144
Alzheimer's disease: The right drug, the right time
Golde, T. E., DeKosky, S. T., & Galasko, D. (2018) · Science · doi:10.1126/science.aau0437 · Cited by 147
Hampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147
de la Torre, J. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180004 · Cited by 145
Ferretti, M. T., Martinkova, J., Biskup, E., Benke, T., Gialdini, G., Nedelska, Z., Rauen, K., Mantua, V., Religa, D., Hort, J., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14174 · Cited by 147
Motor and cognitive deficits in aged tau knockout mice in two background strains
Lei, P., Ayton, S., Moon, S., Zhang, Q., Volitakis, I., Finkelstein, D. I., & Bush, A. I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-29 · Cited by 145
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
Farlow, M. R., Andreasen, N., Riviere, M.-E., Vostiar, I., Vitaliti, A., Sovago, J., Caputo, A., Winblad, B., & Graf, A. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0108-3 · Cited by 144
Self-citationTherapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 155
Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Paricio, M., Lorites, J., Piñol‐Ripoll, G., Gámez, J. E., Anaya, F., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12137 · Cited by 143
Fortea, J., Vilaplana, E., Alcolea, D., Carmona‐Iragui, M., Sánchez‐Saudinos, M., Sala, I., Antón‐Aguirre, S., González, S., Medrano, S., Pegueroles, J., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24186 · Cited by 143
Antibody therapies in CNS diseases
Freskgård, P., & Urich, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.014 · Cited by 152
“For example, in 2012 two Phase III clinical trials of the anti-Ab mAbs bapineuzumab and solanezumab failed to meet their primary clinical endpoints of improved cognition (Doody et al., 2014; Salloway et al., 2014).”
Advances in Alzheimer’s Diagnosis and Therapy: The Implications of Nanotechnology
Hajipour, M. J., Santoso, M. R., Rezaee, F., Aghaverdi, H., Mahmoudi, M., & Perry, G. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.06.002 · Cited by 143
Knopman, D. S., Haeberlein, S. B., Carrillo, M. C., Hendrix, J. A., Kerchner, G., Margolin, R., Maruff, P., Miller, D. S., Tong, G., Tome, M. B., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.002 · Cited by 143
“[49] Doody RS, Thomas RG, FarlowM, Iwatsubo T, Vellas B, Joffe S, et al.”
BackgroundResultSelf-citationIwatsubo, T., Iwata, A., Suzuki, K., Ihara, R., Arai, H., Ishii, K., Senda, M., Ito, K., Ikeuchi, T., Kuwano, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.009 · Cited by 141
Self-citationActive Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
Vandenberghe, R., Riviere, M., Caputo, A., Sovago, J., Maguire, R. P., Farlow, M., Marotta, G., Sanchez‐Valle, R., Scheltens, P., Ryan, J. M., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.003 · Cited by 141
“Recently, two passive immunotherapies (monoclonal antibodies), bapineuzumab and solanezumab, failed to meet their primary end points in cognition and activities of daily living (ADL) in phase-3 trials in patients with mildto-moderate AD [7,8].”
BackgroundSelf-citationXu, M., Mo, X., Huang, H., Chen, X., Liu, H., Peng, Z., Chen, L., Rong, S., Yang, W., Xu, S., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.05.180 · Cited by 137
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy
Clayton, K. A., Van Enoo, A. A., & Ikezu, T. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00680 · Cited by 134
“This was most recently found during Phase 3 of a clinical trial for Solanezumab (Doody et al., 2014).”
BackgroundWeiner, M. W., Nosheny, R., Camacho, M., Truran‐Sacrey, D., Mackin, R. S., Flenniken, D., Ulbricht, A., Insel, P., Finley, S., Fockler, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.021 · Cited by 134
CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation
Kuhlmann, J., Andréasson, U., Pannee, J., Bjerke, M., Portelius, E., Leinenbach, A., Bittner, T., Korecka, M., Jenkins, R. G., Vanderstichele, H., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.05.014 · Cited by 148
“Well MULTI-ARRAY® Human (4G8) Abeta42 Ultra-Sensitive Kit (Meso Scale Discovery, Gaithersburg, MD, USA), 2) Human β Amyloid(1 – 42) ELISA Kit Wako High-Sensitive (Wako Pure Chemical Industries,Ltd., Osaka, Japan), 3) HumanAmyloid β (1 – 42)(N) assay kit - IBL (Immuno-Biological Laboratories Co., Ltd., Fujioka, Japan,…”
InfluentialPérez‐Grijalba, V., Romero, J., Pesini, P., Sarasa, L., Monleón, I., José, I. S., Arbizu, J., Martínez‐Lage, P., Munuera, J., Ruiz, A., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.41 · Cited by 160
“In this line, success of secondary prevention clinical trials may depend on the inclusion of a well-characterised population at pre-dementia stages of the disease (3, 4).”
Animal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132
“, 2012) (Doody et al., 2014)”
What is brain health and why is it important?
Wang, Y., Pan, Y., & Li, H. (2020) · BMJ · doi:10.1136/bmj.m3683 · Cited by 161
Biometals and Their Therapeutic Implications in Alzheimer's Disease
Ayton, S., Lei, P., & Bush, A. I. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0312-z · Cited by 142
Iturria-Medina, Y., Carbonell, F. M., Sotero, R. C., Chouinard-Decorte, F., & Evans, A. C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.02.058 · Cited by 130
“It also provides an efficiency ranking of multiple possible LOAD interventions, which might explain why recent one-target Aβ based therapies failed to improve clinical outcomes in LOAD (Doody et al., 2014; Salloway et al., 2014).”
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
“French and Danish epidemiological studies have shown that moderate wine consumption may protect against development of AD (Dorozynski, 1997; Letenneur et al., 1993; Orgogozo et al., 1997; Truelsen et al., 2002).”
Structure-based drug design identifies polythiophenes as antiprion compounds
Herrmann, U., Schütz, A. K., Shirani, H., Huang, D., Saban, D. V., Nuvolone, M., Li, B., Ballmer, B., Åslund, A., Mason, J. J., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1923 · Cited by 134
Alborixin clears amyloid-β by inducing autophagy through PTEN-mediated inhibition of the AKT pathway
Wani, A., Gupta, M., Ahmad, M., Shah, A. M., Ahsan, A. U., Qazi, P. H., Malik, F., Singh, G., Sharma, P. R., Kaddoumi, A., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1596476 · Cited by 129
The Role and Therapeutic Targeting of α-, β- and γ-Secretase in Alzheimer's Disease
MacLeod, R., Hillert, E.-K., Cameron, R. T., & Baillie, G. S. (2015) · Future Science OA · doi:10.4155/fso.15.9 · Cited by 125
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Mungenast, A. E., Siegert, S., & Tsai, L.-H. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.010 · Cited by 127
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease
Vitek, G., Decourt, B., & Sabbagh, M. N. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2178414 · Cited by 150
“modest clinical efficacy [17], but not both concurrently.”
BackgroundAntiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126
Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 124
“Early clinical trials exhibited minor enhancement in cognitive functions in individuals with moderate AD [244].”
BackgroundBACE inhibition-dependent repair of Alzheimer’s pathophysiology
Keskin, A. D., Kekuš, M., Adelsberger, H., Neumann, U., Shimshek, D. R., Song, B., Zott, B., Peng, T., Förstl, H., Staufenbiel, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708106114 · Cited by 125
Wang, J., Bi, W., Cheng, A., Freire, D., Vempati, P., Zhao, W., Gong, B., Janle, E. M., Chen, T.-Y., Ferruzzi, M. G., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00042 · Cited by 125
Alzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 124
Three-dimensional modeling of human neurodegeneration: brain organoids coming of age
Grenier, K., Kao, J., & Diamandis, P. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0500-7 · Cited by 133
Kim, D., Kwon, H. J., & Hyeon, T. (2019) · Advanced Materials · doi:10.1002/adma.201807965 · Cited by 121
Modulating Gamma Oscillations Promotes Brain Connectivity to Improve Cognitive Impairment
Liu, C., Han, T., Xu, Z., Liu, J., Zhang, M., Du, J., Zhou, Q., Duan, Y., Li, Y., Wang, J., et al. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhab371 · Cited by 141
Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
Gurney, M. E., D'Amato, E. C., & Burgin, A. B. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0309-7 · Cited by 121
Byun, M. S., Yi, D., Lee, J. H., Choe, Y. M., Sohn, B. K., Lee, J.-Y., Choi, H. J., Baek, H., Kim, Y. K., Lee, Y.-S., et al. (2017) · Psychiatry Investigation · doi:10.4306/pi.2017.14.6.851 · Cited by 120
Neuroinflammation in Alzheimer’s disease: insights from peripheral immune cells
Zhang, Q., Yang, G., Luo, Y., Jiang, L., Chi, H., & Tian, G. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00445-0 · Cited by 155
“Subsequent immunother-apies, including the phase 2 bapineuzumab [141] and the phase 3 solanezumab [168, 169], have not improved cognitive impairment in Alzheimer’s patients.”
BackgroundLearning by Failing: Ideas and Concepts to Tackle γ-Secretases in Alzheimer's Disease and Beyond
De Strooper, B., & Chávez Gutiérrez, L. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124309 · Cited by 119
Blood-Based Proteomic Biomarkers of Alzheimer’s Disease Pathology
Baird, A. L., Westwood, S., & Lovestone, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00236 · Cited by 119
Tanaka, H., Homma, H., Fujita, K., Kondo, K., Yamada, S., Jin, X., Waragai, M., Ohtomo, G., Iwata, A., Tagawa, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14353-6 · Cited by 119
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Role of iron in neurodegenerative diseases
Li, K., & Reichmann, H. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1508-7 · Cited by 128
Metadata
- Authors
- Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Pennsylvania (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 311-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015484447
- Cited by
- 1,668
- References
- 28
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 110 · 2023: 116 · 2022: 101 · 2021: 103 · 2020: 154 · 2019: 145 · 2018: 155 · 2017: 163 · 2016: 183 · 2015: 178 · 2014: 111
- FWCI
- 140.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive impairment, activities of daily living, mild to moderate Alzheimer's disease, placebo response
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Cognition, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.